Extracorporeal circuits can cause haemolysis resulting in an increase in plasma-free haemoglobin (PFHb). High pressures and clots within the circuit have been identified as factors increasing the likelihood of haemolysis. Continuous venovenous haemodiafiltration (CVVHD) is associated with high circuit pressures as the pump-driven circuit clots over a period of time. PFHb was measured during CVVHD to determine if circuit life, maximum circuit pressure or the clotting of the haemofilter was associated with evidence of haemolysis. Circuit life up to 50 hours, circuit pressures or haemofilter clotting had no significant effect on PFHb. There was a small rise in PFHb in the circuits lasting beyond 50 hours. CVVHD circuits can be run up to 50 hours without concern for haemolysis.
Continuous renal replacement therapies (CRRT) have become standard treatment for acute renal failure in critically ill patients 1, 2 . The development of pump-driven venovenous circuits utilizing either filtration 3 or diafiltration 4 has overcome the problems of maintenance of circuit flow without arterial access problems and is proposed as the optimal method in acute renal failure 5 . The addition of one of the various anti-coagulation regimens described to the pump-driven circuit, or even anticoagulant-free management in severely coagulopathic patients, has resulted in mean circuit life being extended to 26-35 hours with 15% of circuits lasting greater than 72 hours 6 . Whether it is safe to run CRRT circuits over prolonged periods has not been well established. Some authors have proposed a finite circuit life of 48 hours 7 or 72 hours with earlier immediate change if there is evidence of clot formation 8 . However, it has been our experience that evidence of small amounts of clot at the ends of the haemofilter and at the air/ blood interface in the air detector chamber is common, without any apparent adverse effects, and to change circuits routinely at this stage would reduce the cost-effectiveness of CRRT.
Unlike arteriovenous circuits where cessation due to clotting is very sudden, in pump-driven venovenous circuits clotting can occur over many hours with the pump preserving flow and some function. In a previous study where pre-and post-haemofilter pressures were continuously monitored, we demonstrated that this clotting process resulted in an increase in circuit pressures due to increased resistance across the haemofilter and less commonly across the air detector chamber 9 . The additional monitoring of the pre-haemofilter pressure documented much higher circuit pressures than the routine post-haemofilter pressure monitoring. The mean pre-haemofilter pressure exceeded 300 mm Hg in 12% of circuits, with the pulsatile nature of the pump resulting in even higher transient peaks 9 . While these circuit pressure rises tended to occur rapidly towards the end of the life of a circuit, the circulating blood was often exposed to these pressures over many hours.
In other extracorporeal circuits such as extracorporeal membrane oxygenators, the presence of circuit thrombosis or high pressures has been associated with haemolysis, resulting in the replacement of these circuits 10, 11 . In venovenous CRRT, haemolysis has not been reported and is not considered as a factor in considering circuit change. Therefore we undertook this study to determine whether haemolysis as measured by a rise in plasmafree haemoglobin (PFHb) was associated with venovenous CRRT and whether the magnitude of rise was related to haemofilter clotting, high circuit pressures or haematocrit.
MATERIALS AND METHODS
The study was approved by the institution's Committee on Clinical Investigation.
Access
Vascular access was gained by a 10.8 F, 20 cm double-lumen catheter (Flexicon, Vascath Incorporated, Ontario, Canada). This was inserted via the Seldinger technique into either the subclavian or internal jugular vein. All dialysis catheters were routinely changed at seven days.
Apparatus
The CRRT used was continuous venovenous haemodialysis (CVVHD) utilizing the Gambro System AK10 type BMM10-1 blood monitor. The components of the blood monitor were a roller head pump "arterial" (venous outflow) pressure monitor prior to the pump, "venous" (venous return) pressure monitor at the air detection chamber prior to return to the patient and line clamps. The line clamps were activated by inadequate venous outflow (low "arterial" pressure), the detection of air or excessive venous return pressure, all of which shut down the blood pump.
The circuit lines and haemofilter used were from the Multiflow 60 Kit (Hospal Industrie, Meyzieu, France). The haemofilter was hollow fibre with a wet surface area of 0.75 m 2 (Filtral® AN69®HF membrane). The circuit flow was routinely set at 200 ml/min.
Anticoagulation Protocol
Patients without active bleeding or any other contraindication to heparin were anticoagulated with heparin, aiming for an activated partial thromboplastin time (APTT) of 40 to 80 seconds (control 25 to 29 s). Depending on baseline APTT a bolus of 0 to 5000 units of heparin was given five minutes prior to commencement of CVVHD. Patients with a normal baseline APTT (<35s) received 5000 units. The bolus was reduced to 2500 units for a baseline APTT of 35 to 50 seconds. No starting heparin bolus was given if the baseline APTT was greater than 50 seconds. This was followed by a continuous infusion via the heparin port prior to the blood pump using a syringe pump (Terufusion model STC-521, Terumo, Tokyo, Japan) at a concentration of 10,000 units per 50 ml. Blood samples for APTT were taken from the outflow limb sampling port pre-heparin infusion. A baseline APTT was taken, then four hours after the initial heparin bolus dose and thereafter at eight-hourly intervals. APTT was measured using the Automated Coagu-lation Laboratory 3000 plus (Coulter, Hialeah, U.S.A.).
MEASUREMENT OF PLASMA-FREE HAEMOGLOBIN
The collection of samples for PFHb involved the gentle aspiration of 4 ml of blood over 15 seconds through a 21 gauge needle via the outflow sampling port of the CVVHD circuit. The sample, after removal of the needle, was carefully placed into two lithium heparin vacuette tubes (Greiner, Austria). Two 2 ml samples were taken for duplicate analysis.
Samples were processed in two stages. Within five minutes of collection the first stage involved centrifugation at 150 x g (MSE Super Minor Centrifuge, SK4364, England) for ten minutes. Once complete, the plasma was removed and further centrifuged at 15000 x g for three minutes (Beckman McGofuge E, USA). PFHb estimation was by a rate spectrophotometric method and measured in milligrams Hb per litre 12 . The normal range of PFHb using this method is less than 50 mg/l. Samples were collected daily, prior to the commencement of each circuit, when the post-haemofilter pressure exceeded 250 mmHg and on cessation of the circuit.
Circuit pressures, immediately pre-and posthaemofilter, were measured continuously via purpose-designed T-pieces (Gambro, Pr tconn 2 2) attached to either end of the haemofilter. These pressures were pulsatile and the electronic mean was used to calculate the pressure gradient across the haemofilter (P-grad). The P-grad rises as the haemofilter clots over a period of time due to increased resistance, and we have previously shown that a rise in P-grad above the baseline of greater than 26 mmHg identifies haemofilter clotting 9 . Haematocrit was measured daily and the number of units of homologous blood transfused was recorded. Patients with evidence of disseminated intravascular coagulation or microangiopathy were excluded from this study.
The factors hypothesized to affect PFHb, duration of circuit, haemofilter clotting (P-grad >26 mmHg), peak circuit pressure, haematocrit and blood transfusions were analysed by multiple regression. Data were analysed using the statistical software SPSS for Windows R , Release 6.1.3.
RESULTS
The study included 26 circuits from eight patients with a mean (SD) duration of 31 (38) hours (median 16, range 2 to 186 hours). The longest circuit life was 186 hours and the shortest 12 hours, with five circuits lasting greater than 50 hours. Fourteen circuits fulfilled the criteria of haemofilter clotting with a rise in P-grad exceeding 26 mmHg. The mean (SD) peak circuit pressure was 194 (45) mmHg (median 192, range 77 to 323 mmHg) and haematocrit 32 (5) vol % (median 32, range 20 to 53 Vol %). The mean (SD) number of units of blood during a circuit was 0.88 (2.37) with only five circuits having had a blood transfusion during its course.
There was considerable variation in each circuit commencement PFHb, mean (SD) 102.8 (130.4) mg/l (median 51, range 8 to 540 mg/l), and therefore it was the change in PFHb from the commencement to completion of each circuit that was analysed. The effect of each variable is shown in Table 1 . The effect of time was analysed over two periods. Circuit life up to 50 hours had no significant effect on PFHb. However, circuit life up to 100 hours resulted in a significant predicted rise in PFHb of 56 mg/l. Haemofilter clotting, peak circuit pressures, haematocrit and the number of units of blood per circuit all had no significant effect on PFHb over the life of a circuit. Figure 1 . This predicted relationship, modelled on the change in PFHb in our patients from a starting PFHb of 100 mg/l, shows the significant rise in PFHb after 50 hours (P<0.001). However, the change in PFHb in the small number of circuits that lasted longer than 50 hours was quite variable, mean (SD) 66.9 (310.7) mg/l (median -42.1, range -242 to 613 mg/l).
The relationship between time and PFHb is demonstrated in

DISCUSSION
Pump-driven venovenous CRRT circuits can be maintained over several days without any apparent problems. However, as these circuits are associated with high pressures and circuit clot, we believed that the safety of this practice required the demonstration that significant haemolysis did not occur.
This study did not show any significant haemolysis with CVVHD up to 50 hours. While in circuits lasting longer than 50 hours, there was a statistically significant rise in PFHb (P<0.001), the magnitude of the mean rise in PFHb was small. The level of or rise in PFHb considered to be significant has varied. An increase of up to 40 mg/l has been determined as evidence of no significant haemolysis in association with evaluation of extracorporeal membrane oxygenator circuits 11 . Excessive circuit haemolysis with extracorporeal membrane oxygenator circuits has been defined as a PFHb of >1000 mg/l 13 . The rises in PFHb in this study would appear to be clinically insignificant using these criteria. However, the number of circuits lasting longer than 50 hours in this study was small and caution is needed in this group. It is possible that in individual patients on CVVHD circuits up to and greater than 100 hours, there may be a clinically significant rise in PFHb and the potential for further renal injury. While the variability in baseline PFHb between patients may have reduced the study's power to show a small rise in PFHb, especially in the less than 50 hours group, the level which would cause clinical concern is so much higher that the conclusions remain valid. The full extent of haemolysis may also have been underestimated by not concurrently measuring plasma haptoglobin levels. However, as it is the PFHb that is nephrotoxic, the conclusions of this study remain unchanged.
The utility of CVVHD is enhanced by improving cost-effectiveness of the technique by prolonging circuit life. From a safety point of view haemolysis is not a problem with prolonging circuit use to at least 50 hours, even with evidence of circuit clot. 
